ADIL Adial Pharmaceuticals, Inc.
Healthcare$2.08-9.57%ClosedMarket Cap: $2.0M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
0.77
P/S
0.00
EV/EBITDA
0.34
DCF Value
$7.96
FCF Yield
-326.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-162.8%
ROA
-148.7%
ROIC
-202.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-2.0M | $-2.0M | $— | — |
| Q4 null | $0.00 | NaN% | $-1.9M | $-2.0M | $— | — |
| FY null | $0.00 | NaN% | $-7.8M | $-8.0M | $— | — |
| Q3 null | $0.00 | NaN% | $-1.8M | $-1.8M | $— | — |
| Q2 null | $0.00 | NaN% | $-1.9M | $-2.0M | $— | — |
| Q1 null | $0.00 | NaN% | $-2.3M | $-2.2M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-1.9M | $-2.1M | $— | — |
| FY null | $0.00 | NaN% | $-8.3M | $-13.2M | $— | — |
| Q3 null | $0.00 | NaN% | $-2.2M | $-2.2M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-2.3M | $-2.5M | $— | — |
| Q1 null | $0.00 | NaN% | $-1.8M | $-6.5M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-1.8M | $-1.9M | $-28.75 | — |